Austin, Texas-based XBiotech Inc. said Jan-Paul Waldin was elected to the board and appointed to the audit and compensation committees.
Waldin has been a long-time adviser to the biopharmaceutical company.
With Waldin's appointment, the company has regained compliance with a Nasdaq listing rule regarding board composition.
XBiotech develops antibodies for treating diseases such as cancer, inflammatory conditions, and vascular diseases.
